Following a reduction of the tacrolimus dose to 3 mg daily, blood levels of tacrolimus decreased to 12 ng/mL
PMID: Summary Keywords cardiovascular outcomes, end-stage renal disease, chronic kidney disease, glucagon-like peptide-1 receptor agonists, hemodialysis, real-world evidence, semaglutide, type 2 diabetes mellitus Citation Alkhezi O, Alfehaid L, Alanezi A, Alotaibi M and Alshaya O (2026) Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study
Allergy 69(4):420437
Wegovy (semaglutide) Injector is a prescription medication used to treat obesity in adults who have a body mass index (BMI) of 30 kg/m or greater, or in adults with a BMI of 27 kg/m or greater who also have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol
Res (2018) 16:26